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Introduction: Bone marrow mesenchymal stem cells (BMMSCs) have been reported to facilitate liver regeneration
after toxic injuries. However, the effect of BMMSCs on liver regeneration after massive hepatectomy is barely
studied. Here we explored whether infusion of BMMSCs promotes liver regeneration in a rat massive hepatectomy
model.
Methods: Hypoxia preconditioning was achieved by culturing BMMSCs under a hypoxia environment. Then 85%
hepatectomy was performed and hypoxia or normoxia preconditioned BMMSCs were infused into the portal vein.
A group of rats received vascular endothelial growth factor (VEGF) neutralizing antibody perioperatively, and
underwent 85% hepatectomy and a subsequent infusion of hypoxia preconditioned BMMSCs to verify the role of
VEGF in the effects of BMMSCs on liver regeneration. Liver samples were collected and liver regeneration was
evaluated postoperatively.
Results: Hypoxia preconditioning enhanced the expression of VEGF in BMMSCs in vitro. Infusion of BMMSCs
promoted proliferation of hepatocytes, reflected by elevated cyclin D1 expression and proliferating cell nuclear
antigen-positive hepatocytes. However, BMMSC infusion did not improve the serum albumin level, liver weight/
body weight ratio, and survival after operation. Infusion of hypoxia preconditioned BMMSCs significantly elevated
cyclin D1, proliferating cell nuclear antigen-positive hepatocytes, liver weight/body weight ratio, and survival
compared with normoxia preconditioned BMMSCs, accompanied by an increased serum albumin level. The level of
VEGF in liver homogenate was much higher in hypoxia preconditioned BMMSC-treated animals than in other
groups. In addition, the perioperative injection of VEGF neutralizing antibody significantly blocked the therapeutic
effects of hypoxia preconditioned BMMSCs on liver injury and regeneration in this model.
Conclusion: Hypoxia preconditioned BMMSCs enhanced liver regeneration after massive hepatectomy in rats,
possibly by upregulating the level of VEGF.
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The liver is the only human organ that is capable of nat-
ural restoration of lost tissue, mainly by proliferation of
previously quiescent hepatocytes. As little as 25% of a
liver is reported to be able to regenerate into a whole
liver in a short period. However, in some severe condi-
tions, such as acute liver failure or end-stage liver dis-
eases, the proliferation of hepatocytes is insufficient or
seriously impaired, leading to failure of liver function. At
present, the only therapeutic choice for acute liver fail-
ure and end-stage liver diseases is liver transplantation.
However, as long as the donor shortage continues to be
the rate-limiting step in the expansion of liver trans-
plantation, work on exploring alternative forms of ther-
apies is still needed.
Stem cell-based therapy is emerging to be an effective
treatment in many diseases. Adult mesenchymal stem
cells (MSCs) have recently received attention for their
availability and ability to differentiate down multiple lin-
eages [1,2]. Bone marrow mesenchymal stem cells
(BMMSCs) are one type of MSCs derived from bone
marrow and are considered a promising cell source in
treating various liver disorders [3-5]. Systemic infusion
of BMMSCs into rodents subjected to toxic liver injuries
is confirmed to restore liver function and promote liver
regeneration [5]. Some clinical trials also indicate that
infusion of BMMSCs benefits patients with end-stage
liver diseases [6-8].
Although BMMSCs have been shown to attenuate
liver injuries and promote liver regeneration, the under-
lying mechanisms are still not clear. Transdifferentiation
into the hepatic lineage is not considered a convincing
explanation because there is no solid evidence. Cell fu-
sion may better explain the coexpression of hepatic and
MSC markers [9,10]. On the other hand, the paracrine
effect of BMMSCs is drawing increasing attention and is
thought to be the main mechanism of its therapeutic ef-
fects. MSC-conditioned medium therapy has been
reported to provide trophic support to the injured liver
by inhibiting hepatocellular death and stimulating regen-
eration [11], highlighting the role of MSC-derived sol-
uble factors in attenuating liver injury and promoting
liver regeneration. BMMSCs secrete many growth fac-
tors, cytokines and chemokines, including vascular
endothelial growth factor (VEGF), hepatocyte growth
factor, IL-6, and stromal cell-derived factor-1 [12].
Among these factors, VEGF is an important growth and
proangiogenic factor, and is regarded as the key factor
secreted by BMMSCs in treating many diseases [13-16].
VEGF is also considered an important factor during liver
regeneration [17,18]. BMMSCs might therefore promote
liver regeneration by secreting VEGF and other trophic
factors. BMMSCs are reported to produce more growth
factors under a hypoxic environment [19], and hypoxiapreconditioning is confirmed to be an effective way to
enhance their therapeutic potential [20,21]. Hypoxia
preconditioning of BMMSCs might therefore enhance
their effect on liver regeneration by upregulating the se-
cretion of VEGF.
Here we explored whether infusion of normoxia or
hypoxia preconditioned BMMSCs promotes liver regen-
eration in a rat 85% hepatectomy model. The role of
BMMSC-derived VEGF was also evaluated by measuring
the cells’ expression in vitro and in vivo.
Materials and methods
Isolation and culture of BMMSCs
BMMSCs were isolated from rat femoral bone marrow.
In brief, the marrow pellet was washed in Hanks’ bal-
anced salt solution, centrifuged at 1,000 rpm for 10 mi-
nutes and then resuspended in DMEM (Gibco, Grand
Island, NY, USA) containing 10% fetal bovine serum
(Gibco), penicillin (100 U/ml), and streptomycin (100
mg/ml). The nucleated cells were cultured at 37°C in a
humidified 5% CO2 atmosphere. The medium was
replenished 24 hours later to remove the nonadherent
cells and every 3 days thereafter. For subculture, cells
were resuspended with 0.25% trypsin and passaged at a
ratio of one to three plates.
For analysis of cell surface markers, passage 3 cells
were incubated with fluorescein isothiocyanate-
conjugated mouse antibodies against rat CD11c, CD29,
CD45, and CD90 (Caltag Laboratories, San Francisco,
CA, USA) and analyzed by flow cytometry. Most of
these cells expressed CD29 and CD90, and few
expressed CD11c and CD45 (Figure 1a).
The multipotency of isolated cells was evaluated
using adipogenic and osteogenic assays. Briefly, passage
3 cells were cultured in DMEM containing 10% fetal
bovine serum, antibiotics, 200 mM indomethacin, 1
mM dexamethasone, 0.5 mM 3-isobutyl-1-methylxan-
thine and 10 g/l insulin (Sigma-Aldrich, St Louis, MO,
USA) for adipogenic induction or in DMEM containing
10% fetal bovine serum, antibiotics, 50 mg/l L-ascor-
bate-2-phosphate, 0.1 μM dexamethasone, 10 mM β-
glycerophosphate(Sigma–Aldrich) for osterogenic in-
duction. Four weeks later, oil Red O and alizarin red
stainings were performed to detect the lipid droplets
and matrix mineralization in induced cells respectively
(Figure 1b).
Hypoxia-preconditioning of BMMSCs
Passage 3 to 5 BMMSCs were suspended using 0.25%
trypsin and plated into new dishes in 5 × 105/ml. The
media was refreshed 24 hours later and cells were cul-
tured under 1% oxygen, 5% CO2, and 94% nitrogen for
another 24 hours. After 24 hours’ hypoxic culture, these
cells were immediately harvested and resuspended in
Figure 1 Expression of several surface markers and multi-potential of bone marrow mesenchymal stem cells. (a) Most of the isolated
bone marrow mesenchymal stem cells (BMMSCs) expressed CD29 and CD90, few expressed CD11c and CD45. (b) Matrix mineralization (arrows)
or lipid droplets (arrow heads) were seen in cells cultured in osteogenic or adipogenic medium for 4 weeks. n = 6, scale bar represents 10 μm.
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The levels of VEGF in the supernatant were measured
using a rat VEGF ELISA kit (R&D systems, Minneapolis,
MN, USA), following the manufacturer’s protocol. The
experiment was repeated three times. At least six plates
per experiment were used in each group.Experimental design and rat 85% hepatectomy
Male Sprague–Dawley rats were purchased from
Shanghai Laboratory Animal Center, Chinese Academy
of Sciences. The animals were housed in a controlled
12-hour light/dark cycle environment with chow and
water ad libitum. The animal experiments were
performed according to guidelines for animal care of
Zhejiang University and approved by the Animal Ethics
Review Committees of Zhejiang University.
A total of 156 rats were used in this study. They were
divided into four groups: control group (n = 24), rats
underwent 85% hepatectomy and received 1 ml saline;
N-BMMSC group (n = 24), rats underwent 85% hepatec-
tomy and received 5 × 106 normoxia-conditioned
BMMSCs in 1 ml saline; H-BMMSC group (n = 24), rats
underwent 85% hepatectomy and received 5 × 106
hypoxia-conditioned BMMSCs in 1 ml saline; and H-
BMMSC + VEGF mAb group (n = 24), rats underwent
85% hepatectomy, received 5 × 106 hypoxia-conditioned
BMMSCs in 1 ml saline, and were injected (intraperito-
neally) with VEGF mAb (100 μg/mouse) six timesperioperatively. Another 15 rats from each group were
used for the survival study.
The 85% hepatectomy was performed according to the
published method [22]. Briefly, after general anesthesia
with sodium pentobarbital (30 to 50 mg/kg, intraperito-
neally), rat middle lobes, left lateral lobe, caudate lobes
and right inferior lobe were ligated and resected. Subse-
quently, 1 ml saline with or without 5 × 106 BMMSCs
was infused into the portal vein. After operation, rats
were allowed to spontaneously recover, and no further
treatment was given. The hepatectomy was performed
by an experienced technician. All animals survived the
surgical procedure in this study. Rats were sacrificed 24,
36, 72, and 168 hours after operation. Liver weight and
body weight were measured. Serum and liver samples
were collected for analysis.
Real-time RT-PCR
Total mRNA was extracted from frozen tissue samples
by Trizol (Invitrogen, Carlsbad, CA, USA) and reverse
transcribed using an RT reagent kit (TaKaRa, Shiga,
Japan). Real-time PCR was performed using an ABI
7900 Sequence Detection System (Applied Biosystems,
Foster City, USA) with SYBR-green I (TaKaRa).
The primer sequences were listed as follows: cyclin
D1 – sense, 5′-CTTCAAGTGCGTGCAGAGGGAG-3′
and anti-sense, 5′-GTAGTTCATGGCCAGCGGGAAG-3;
VEGF – sense, 5′-TGCACTGGACCCTGGCTTTAC-3′
and anti-sense, 5′-CGGCAGTAGCTTCGCTGGTAG-3′;
Figure 2 Vascular endothelial growth factor in bone marrow
mesenchymal stem cells incubated under normoxia or hypoxia.
Levels of vascular endothelial growth factor (VEGF) in supernatant of
bone marrow mesenchymal stem cells incubated under normoxia or
hypoxia conditions for 24 hours. n = 6, *P <0.05.
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GAC-3′ and anti-sense, 5′-AGGTCTTTACGGATGTC
AACGT-3′. Relative gene expression profiles were deter-
mined by normalizing to the housekeeping gene (β-actin)
using the 2−(ΔΔCt) method [23].
Western blot
Total proteins were extracted in cell lysis buffer with
protease and phosphatase inhibitors. Proteins were
quantified using protein assay (Bio-Rad Laboratories,
Hercules, CA, USA), and 50 mg protein was separated
by SDS-PAGE and transferred to 0.2 mm polyvinyl
difluoride membranes. Membranes were blocked in
Tris-buffered saline, 0.1% Tween 20, and 5% BSA for 2
hours before overnight incubation with polyclonal rabbitFigure 3 mRNA and protein levels of cyclin D1 postoperatively. (a) mR
PCR. (b) Protein expression of cyclin D1 24, 36, and 72 hours postoperative
conditioned bone marrow mesenchymal stem cells; N-BMMSC, normoxia-c
endothelial growth factor.antibodies against rat cyclin D1 and VEGF (diluted 1:2,000
in Tris-buffered saline 0.1% Tween 20 and 5% BSA;
Abcam, Cambridge, MA, USA). The membranes were in-
cubated for 1 hour in horseradish-peroxidase-conjugated
goat anti-rabbit IgG (eBioscience, San Diego, CA, USA) at
a dilution of 1:2,000 in Tris-buffered saline, 0.1% Tween
20 and 5% BSA. Immunoreactive protein was detected
using ECL (GE Healthcare, Chalfont St Giles, UK) and
BioMaxfilm (Kodak, Rochester, NY, USA).
Immunohistological assay
Paraffin-embedded liver sections were stained for prolif-
erating cell nuclear antigen (PCNA). Liver slides were
stained with rabbit polyclonal antibody to PCNA (1:100;
Santa Cruz Technology, Santa Cruz, CA, USA) at 4°C
overnight. The sections were incubated with second
antibodies and stained with chromogenic substrate solu-
tion. The amount of PCNA-positive cells was counted
by two independent and blinded reviewers. Briefly, they
calculated the PCNA-positive cells (with brown nuclei)
of four independent microscopic fields (×40) per section
and two sections per animal.
ELISA of liver homogenate for VEGF
Snap-frozen liver samples were thawed on ice, weighed,
and homogenized in solution containing 2 mg protease
inhibitor (Sigma-Aldrich) per milliliter of normal saline.
The expression of VEGF in liver homogenate was evalu-
ated by ELISA according to the manufacturer’s protocol.
Statistical analysis
Data were analyzed using SPSS 16.0 software (SPSS,
Chicago, IL, USA). One-way analysis of variance was
used to compare group variables, followed by Tukey’sNA level of cyclin D1 24, 36, and 72 hours postoperatively by real-time
ly by western blot. n = 6, *P <0.05 and **P <0.01. H-BMMSC, hypoxia-
onditioned bone marrow mesenchymal stem cells; VEGF, vascular
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was performed for distributions for which equal vari-
ances could not be assumed. All values were expressed
as mean ± standard deviation. P <0.05 was considered
significant. To analyze the 7-day survival rate, the
Kaplan–Meier method and log-rank test was applied.
Results
Hypoxia preconditioning enhanced the secretion of VEGF
by BMMSCs
To explore whether the secretion of VEGF by BMMSCs
was enhanced under hypoxic conditions, we culturedFigure 4 Proliferating cell nuclear antigen expression in liver slides o
nuclear antigen (PCNA)-positive. Scale bar represents 20 μm. n = 6, *P <0.05
mesenchymal stem cells; N-BMMSC, normoxia-conditioned bone marrow mBMMSCs in hypoxic conditions for 24 hours. The super-
natant was collected for ELISA of VEGF. The level of
VEGF in supernatant of hypoxia-conditioned BMMSCs
was significantly higher than in normoxia-conditioned
BMMSCs (101.1 ± 12.02 pg/105 cells vs. 568.5 ± 34.79
pg/105 cells, P <0.01; Figure 2).
Normoxia-conditioned BMMSCs promoted proliferation of
hepatocytes but not liver regeneration and survival
We explored the therapeutic effect of normoxia-
conditioned BMMSCs in our massive hepatectomy
model. The mRNA and protein levels of cyclin D1n postoperative day 3. Cells with brown nuclei were proliferating cell
and **P <0.01. H-BMMSC, hypoxia-conditioned bone marrow
esenchymal stem cells; VEGF, vascular endothelial growth factor.
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higher than those in the control group postoperatively
(Figure 3), indicating a higher level of DNA synthesis in
the N-BMMSC group. Similarly, the percentage of
PCNA-positive cells was higher in the N-BMMSC group
than in the control group on postoperative day 3 (42.28
± 5.288 vs. 34.33 ± 5.602, P <0.05; Figure 4). However, no
significant difference was seen in serum albumin levels
(Figure 5) and the liver weight/body weight ratio be-
tween these two groups at 24, 36, 72, and 168 hours
postoperatively (Figure 6a). In addition, 7-day survival
rates were similar between these two groups (40% in
control group vs. 46.7% in the N-BMMSC group;
Figure 6b).
Hypoxia-conditioned BMMSCs reduced liver injury, and
enhanced proliferation of hepatocytes, liver regeneration
and survival
To maximize the therapeutic potential of infused
BMMSCs, we evaluated the effects of hypoxia
preconditioned BMMSCs on liver injury and regener-
ation in this massive hepatectomy model. We found that
the serum level of albumin significantly increased in the
H-BMMSC group compared with the N-BMMSC and
control groups (Figure 5). The mRNA and protein levels
of cyclin D1 (Figure 3) and percentage of PCNA-positive
cells (Figure 4) were further elevated in the H-BMMSC
group compared with those in the N-BMMSC group. In
addition, the liver weight/body weight ratio and 7-day
survival rate of the H-BMMSC group were significantly
higher than that of the N-BMMSC and control groups
(Figure 6a,b).Figure 5 Serum albumin levels 24, 36, 72, and 168 hours postoperati
bone marrow mesenchymal stem cells; N-BMMSC, normoxia-conditioned b
growth factor.VEGF mRNA and protein levels were elevated in hypoxia-
conditioned BMMSCs
The level of VEGF mRNA was much higher in the H-
BMMSC group than in the control and N-BMMSC
groups 24, 72, and 168 hours postoperatively (Figure 7a).
Similarly, the level of VEGF in liver homogenate of the
H-BMMSC group was much higher than in the control
and N-BMMSC groups 24, 72, and 168 hours postopera-
tively (Figure 7b).
Injection of VEGF mAb diminished the therapeutic effect
of hypoxia-conditioned BMMSCs
To evaluate the possible involvement of the elevated
VEGF in the H-BMMSC therapeutic effect, we injected
rat VEGF mAb into perioperative rats. We found after
VEGF was inhibited by the antibody that the therapeutic
effects of H-BMMSCs were mostly diminished. The ex-
pression of cyclin D1 (Figure 3), percentage of PCNA-
positive cells (Figure 4), liver weight/body weight ratio
(Figure 6a) and 7-day survival rate (Figure 6b) in the H-
BMMSC + VEGF mAb group all significantly declined
compared with the H-BMMSC group. The serum albu-
min level was significantly lower in the H-BMMSC +
VEGF mAb group than in the H-BMMSC group
(Figure 5). These results indicated that VEGF may play
an important role in H-BMMSC pro-regenerative effects.
Discussion
BMMSCs are reported to reduce liver injuries and pro-
mote liver regeneration in many animal models. The
therapeutic effects vary, and the underlying mechanisms
are distinct, sometimes controversial. These variationsvely. n = 6, *P <0.05 and **P <0.01. H-BMMSC, hypoxia-conditioned
one marrow mesenchymal stem cells; VEGF, vascular endothelial
Figure 6 Remnant liver volume and survival of postoperative
animals. (a) Liver weight/body weight ratios 24, 36, 72, and 168
hours postoperatively. (b) Seven-day survival curves of postoperative
animals. n = 6, *P <0.05 and **P <0.01 when comparing data of the
H-BMMSC group with data of the other three groups. H-BMMSC,
hypoxia-conditioned bone marrow mesenchymal stem cells; N-
BMMSC, normoxia-conditioned bone marrow mesenchymal stem
cells; VEGF, vascular endothelial growth factor.
Figure 7 mRNA and protein levels of vascular endothelial
growth factor in rat liver postoperatively. (a) mRNA level of VEGF
24, 72, and 168 hours postoperatively by real-time PCR. (b) Protein
expression of VEGF 24, 72, and 168 hours postoperatively by ELISA.
n = 6, **P <0.01). H-BMMSC, hypoxia-conditioned bone marrow
mesenchymal stem cells; N-BMMSC, normoxia-conditioned bone
marrow mesenchymal stem cells; VEGF, vascular endothelial
growth factor.
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toxic liver injuries using agents such as Carbon tetrachlo-
ride and D-galactosamine. The accompanying chemical
injuries may affect the process of liver regeneration by al-
tering the release of cytokines and directly inhibiting the
proliferation of hepatocytes. Here we introduced a rat
model of massive hepatectomy. The regeneration stimuli
are adequate, and some degree of liver injury exists.
In this study, we found that infusion of BMMSCs may
facilitate the proliferation of hepatocytes after massive
hepatectomy in rats, reflected by the elevated expression
of cyclin D1 and PCNA-positive cells. However, the infu-
sion neither reduces liver injury nor accelerates the
process of liver regeneration. These results are similar toreports from our researchers. Hu and colleagues demon-
strated that normoxia-conditioned MSCs have little
effect on rat infarcted myocardium, but hypoxia
preconditioning significantly enhances the capacity of
MSCs to reduce cell death and apoptosis, increasing
angiogenesis/visualization [24]. The pro-regenerative po-
tential of normoxia-conditioned BMMSCs may therefore
be less impressive.
Hypoxia preconditioning for MSCs was first reported
by Annabi and colleagues, who found that hypoxia en-
hances the expression of VEGF and MT1-matrix
metalloproteinase and facilitates migration and tube
formation of MSCs [20]. More data showed that, after
incubating MSCs in hypoxic environments, the bio-
logical features of these cells are apparently altered. This
alteration is characterized by upregulation of several
pro-regenerative, pro-angiogenic, and anti-apoptotic
factors such as hypoxia-inducible factor-1α, VEGF and
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was confirmed to be an effective way of enhancing the
therapeutic effects of MSCs in many diseases. Rosová
and colleagues demonstrate that MSCs enhanced revas-
cularization after surgical induction of hind limb ische-
mia in mice, and the restoration of blood flow was
observed significantly earlier in mice that had been
injected with hypoxic preconditioned MSCs [21]. Other
researchers also reported similar results in a myocardial
infarction model [28] and in a traumatic brain injury
model [29].
Here we found that hypoxia-conditioned BMMSCs se-
creted significantly more VEGF than normoxia-
conditioned cells. The levels of VEGF mRNA and pro-
tein were also upregulated postoperatively in the H-
BMMSC group. Taken together, these results indicated
that elevated VEGF might play the key role in the H-
BMMSC therapeutic effect in this model. The periopera-
tive application of VEGF mAb successfully blocked the
H-BMMSC effects in promoting liver regeneration, fur-
ther supporting this hypothesis. VEGF is considered an
important regulator in liver regeneration. Some studies
report that delivery of VEGF increases liver mass in vivo
but does not promote proliferation of hepatocytes
in vitro, unless liver sinusoidal endothelial cells are also
present, indicating that VEGF promotes liver regener-
ation via stimulating the proliferation of liver sinusoidal
endothelial cells [17]. VEGF treatment can also signifi-
cantly reduce the mortality rate of rats subjected to
acute liver failure through maintenance of liver sinus-
oidal endothelial cell architecture [30]. Ding and col-
leagues reported the VEGF-dependent regenerative
stimuli are important in inducing proliferation of mature
hepatocytes after partial hepatectomy, highlighting the
role of VEGF in liver regeneration [18]. Now widely ac-
cepted is that liver regeneration is an angiogenesis-
dependent phenomenon, and liver sinusoidal endothelial
cells are a key mediator of liver regeneration after partial
hepatectomy [31,32]. Hence, BMMSC-derived VEGF
might promote liver regeneration by enhancing the re-
generation of liver sinusoidal endothelial cells and hepa-
tocytes in this model. In addition, the dynamic
expression of VEGF after operation in this study further
confirmed this hypothesis. We found that the peak of
VEGF expression in this study occurred at 72 hours,
which coincided with the proliferation of liver sinusoidal
endothelial cells in liver regeneration [33].
Although the in vitro experiment showed that
BMMSCs secreted much more VEGF by hypoxia
preconditioning, the in vivo upregulation of VEGF may
only partially be due to elevated production of VEGF by
infused H-BMMSCs. As liver parenchymal cells also
produce VEGF and the production might be regulated
by surrounding BMMSCs. IL-6 [34], hepatocyte growthfactor [18], and insulin-like growth factor-1 [35], which
could be secreted by BMMSCs, are reported to promote
the production of VEGF. The infused H-BMMSCs might
therefore indirectly upregulate the expression of VEGF
in liver parenchymal cells. However, the expressions of
other factors such as IL-6 and hepatocyte growth factor
after hypoxia conditioning need further exploration.
The transdifferentiation potential of infused BMMSCs
was not evaluated in this study. The consensus is that
the main therapeutic effects of MSCs are their paracrine
function of various factors but not differentiating into
functional tissue cells. Taking cell fusion into consider-
ation, few, if any, infused MSCs transdifferentiate into
functional liver cells [36], and the duration for successful
differentiation of MSCs is reported to be at least 2 weeks
[37]. Perhaps it is therefore of little value to assess the
possible differentiation of infused BMMSCs within 1
week after implantation.
Conclusion
In summary, we found that the infusion of hypoxia
preconditioned BMMSCs reduced liver injury and pro-
moted liver regeneration and survival in a rat massive
hepatectomy model. The upregulation of VEGF might
mediate the therapeutic effects of infused BMMSCs. Fur-
ther studies are needed to evaluate the exact cell source
of up-expressed VEGF and the mechanisms of its pro-
regenerative effects in this model.
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